Alpha Cognition Inc (ACOG)
ACOG Stock Price Chart
Explore Alpha Cognition Inc interactive price chart. Choose custom timeframes to analyze ACOG price movements and trends.
ACOG Company Profile
Discover essential business fundamentals and corporate details for Alpha Cognition Inc (ACOG) to support your stock research and investment decisions.
Sector
Financial Services
Industry
Financial - Conglomerates
IPO Date
12 Nov 2024
Employees
71.00
Website
https://www.alphacognition.comCEO
Michael E. McFadden
Description
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
ACOG Financial Timeline
Browse a chronological timeline of Alpha Cognition Inc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.39, while revenue estimate is $4.38m.
Earnings released on 14 May 2026
EPS came in at -$0.37 surpassing the estimated -$0.41 by +9.76%, while revenue for the quarter reached $3.53m , beating expectations by +3.25%.
Earnings released on 26 Mar 2026
EPS came in at -$0.30 falling short of the estimated -$0.27 by -11.11%, while revenue for the quarter reached $2.80m , missing expectations by -12.54%.
Earnings released on 13 Nov 2025
EPS came in at -$0.30 surpassing the estimated -$0.43 by +30.23%, while revenue for the quarter reached $2.84m , missing expectations by -45.99%.
Earnings released on 14 Aug 2025
EPS came in at -$0.65 falling short of the estimated -$0.46 by -41.30%, while revenue for the quarter reached $1.66m , missing expectations by -60.11%.
Earnings released on 15 May 2025
EPS came in at -$0.20 surpassing the estimated -$0.58 by +65.52%, while revenue for the quarter reached $2.93m , beating expectations by +485.73%.
Earnings released on 31 Mar 2025
EPS came in at -$0.51 falling short of the estimated -$0.48 by -6.25%.
Earnings released on 14 Nov 2024
EPS came in at -$0.31 surpassing the estimated -$1.00 by +69.00%.
Stock split effective on 5 Nov 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Aug 2024
EPS came in at -$0.35 surpassing the estimated -$1.00 by +64.80%.
Earnings released on 31 Mar 2024
EPS came in at -$0.87 .
Earnings released on 31 Dec 2023
EPS came in at -$1.55 .
Earnings released on 30 Sept 2023
EPS came in at -$0.84 .
Earnings released on 30 Jun 2023
EPS came in at -$0.74 .
Earnings released on 31 Mar 2023
EPS came in at -$0.60 .
Earnings released on 31 Dec 2022
EPS came in at -$1.25 .
Earnings released on 30 Sept 2022
EPS came in at -$0.76 .
Earnings released on 30 Jun 2022
EPS came in at -$1.10 .
Earnings released on 31 Mar 2022
EPS came in at -$1.08 .
Earnings released on 31 Dec 2021
EPS came in at -$2.29 .
Earnings released on 30 Sept 2021
EPS came in at -$2.07 .
ACOG Stock Performance
Access detailed ACOG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
